TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21326271

Group type: EXPERIMENTAL
Intervention: Extra virgin olive oil
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Soy oil
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Cod liver oil
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Corn oil
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: All types of oil
Number of subjects: 67
Study: 19259349

Group type: EXPERIMENTAL
Intervention: Postoperative prophylactic antibiotics (1.0 g Cefpiramide twice daily until the third day after surgery)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group (no postoperative prophylactic antibiotics)
Number of subjects: 56
Study: 17239889

Group type: EXPERIMENTAL
Intervention: Low levels of adiponectin (lowest quartile)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Adiponectin levels (second to fourth quartile)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Baseline measures of IMT and distensibility
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: After 12 months
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Adjustment for confounding factors
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Leptin levels
Number of subjects: 142
Study: 15088038

Group type: EXPERIMENTAL
Intervention: CO2 laser irradiation (wavelength 10.6 mm)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control samples (not subjected to laser irradiation)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: MTA (root end filling material)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Gutta percha (root end filling material)
Number of subjects: 40
Study: 11682393

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 0

Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 0
Study: 8860099

Group type: EXPERIMENTAL
Intervention: Captopril 12.5 mg (LD-CAP)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Captopril 50 mg (HD-CAP)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 2179367

Group type: EXPERIMENTAL
Intervention: Controlled-release albuterol
Number of subjects: 124

Group type: COMPARATOR
Intervention: Sustained-release theophylline
Number of subjects: 124
Study: 94402

Group type: COMPARATOR
Intervention: Probucol, 500 mg twice daily for 20 weeks
Number of subjects: 9
Study: 30840640

Group type: EXPERIMENTAL
Intervention: High physical exertion and high cognitive engagement (combo group)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Low physical exertion and high cognitive engagement (cognition group)
Number of subjects: 142

Group type: COMPARATOR
Intervention: High physical exertion and low cognitive engagement (aerobic group)
Number of subjects: 142
Study: 28514081

Group type: EXPERIMENTAL
Intervention: Weight Loss Plus
Number of subjects: 409

Group type: COMPARATOR
Intervention: Weight Loss Only
Number of subjects: 409
Study: 25876706

Group type: EXPERIMENTAL
Intervention: Oral OKT3 5.0 mg/day (Group D)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Oral OKT3 1.0 mg/day (Group C)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Oral OKT3 0.2 mg/day (Group B)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo (Group A)
Number of subjects: 36
Study: 25016366

Group type: EXPERIMENTAL
Intervention: Behavior activation (BA) + low vision rehabilitation (LVR)
Number of subjects: 188

Group type: COMPARATOR
Intervention: Supportive therapy (ST) + low vision rehabilitation (LVR)
Number of subjects: 188
Study: 22503761

Group type: EXPERIMENTAL
Intervention: Exisulind (375‐400 mg) daily for 4 weeks
Number of subjects: 93

Group type: COMPARATOR
Intervention: Control group (routine RP)
Number of subjects: 93
Study: 20607509

Group type: EXPERIMENTAL
Intervention: Hamstring tendon grafts (ST and GT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bone-patellar-tendon graft (BPT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both grafts (Hamstring and BPT)
Number of subjects: 0
Study: 17591514

Group type: EXPERIMENTAL
Intervention: Educational program designed to improve care for somatizing patients
Number of subjects: 911

Group type: COMPARATOR
Intervention: Control group (no educational program)
Number of subjects: 911
Study: 16261546

Group type: EXPERIMENTAL
Intervention: Balloon angioplasty
Number of subjects: 450

Group type: COMPARATOR
Intervention: Stent implantation
Number of subjects: 450
Study: 12117397

Group type: EXPERIMENTAL
Intervention: Estrogen plus progestin (conjugated equine estrogens 0.625 mg/d plus medroxyprogesterone acetate 2.5 mg/d)
Number of subjects: 16608
Study: 10421920

Group type: EXPERIMENTAL
Intervention: Ropivacaine pre-operative injection (3 ml, 7.5 mg/ml)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Ropivacaine post-operative injection (3 ml, 7.5 mg/ml)
Number of subjects: 80

Group type: COMPARATOR
Intervention: NaCl pre-operative injection (3 ml)
Number of subjects: 80

Group type: COMPARATOR
Intervention: NaCl post-operative injection (3 ml)
Number of subjects: 80
Study: 8862216

Group type: EXPERIMENTAL
Intervention: Medication Event Monitoring System (MEMS)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Pill count
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Both MEMS and pill count adherence
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Nonadherence by one or both methods
Number of subjects: 94
Study: 1346408

Group type: EXPERIMENTAL
Intervention: Intramuscular artemether (4 mg/kg loading dose followed by 2 mg/kg daily)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Intramuscular chloroquine (3.5 mg base/kg every 6 h)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Intramuscular artemether
Number of subjects: 73

Group type: COMPARATOR
Intervention: Intramuscular chloroquine
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Intramuscular artemether and chloroquine
Number of subjects: 73
Study: 6429092

Group type: EXPERIMENTAL
Intervention: Daily fractionation of radiation (12-13 MeV electron beams)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Twice-a-week fractionation of radiation (12-13 MeV electron beams)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cumulative radiation effect (CRE) formula
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Iso-effect relationship
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dose range of 30 fractions between 1.6 and 2.1 Gy in 6 weeks
Number of subjects: 0
Study: 30804310

Group type: EXPERIMENTAL
Intervention: Probiotic lozenge (twice daily for 1 month)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo lozenge (twice daily for 1 month)
Number of subjects: 60
Study: 29907956

Group type: EXPERIMENTAL
Intervention: Combined fractional CO2 laser and long pulsed Nd : YAG (1064 nm) laser
Number of subjects: 20

Group type: COMPARATOR
Intervention: Long pulsed Nd : YAG (1064 nm) laser
Number of subjects: 20
Study: 27286045

Group type: EXPERIMENTAL
Intervention: MIPPO
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: IMN
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: EF + LORIF
Number of subjects: 84

Group type: COMPARATOR
Intervention: EF + LORIF, MIPPO, IMN
Number of subjects: 84
Study: 25407583

Group type: EXPERIMENTAL
Intervention: Telephone-administered cognitive behavioral therapy (T‐CBT)
Number of subjects: 325

Group type: COMPARATOR
Intervention: Face-to-face administered cognitive behavioral therapy (FtF‐CBT)
Number of subjects: 325
Study: 22464708

Group type: EXPERIMENTAL
Intervention: Endovascular simulator training (group A and group B)
Number of subjects: 80

Group type: COMPARATOR
Intervention: No further training (group A after initial exposure)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Endovascular simulator training (group B after initial exposure)
Number of subjects: 80
Study: 20816836

Group type: EXPERIMENTAL
Intervention: 180 μg/wk peginterferon alfa‐2a for 48 weeks plus 1200 mg/day ribavirin (group A)
Number of subjects: 1145

Group type: EXPERIMENTAL
Intervention: 1400/1600 mg/day ribavirin (group B)
Number of subjects: 1145

Group type: EXPERIMENTAL
Intervention: 360 μg/wk peginterferon alfa‐2a for 12 weeks then 180 μg/wk peginterferon alfa‐2a for 36 weeks plus 1200 mg/day ribavirin (group C)
Number of subjects: 1145

Group type: EXPERIMENTAL
Intervention: 1400/1600 mg/day ribavirin (group D)
Number of subjects: 1145

Group type: COMPARATOR
Intervention: Pooled peginterferon alfa‐2a regimens (A + B)
Number of subjects: 1145

Group type: COMPARATOR
Intervention: Pooled ribavirin regimens (A + C)
Number of subjects: 1145
Study: 17993096

Group type: EXPERIMENTAL
Intervention: Propofol in a mixture of 50% N2O and 50% oxygen (group P2)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Thiopental in a mixture of 50% N2O and 50% oxygen (group T2)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Propofol in 100% oxygen (group P1)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Thiopental in 100% oxygen (group T1)
Number of subjects: 160
Study: 15452896

Group type: EXPERIMENTAL
Intervention: Pre-loss levels of posttraumatic stress symptoms (intrusion and avoidance)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Post-loss levels of posttraumatic stress symptoms
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Current level of perceived stress
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Anticipated impact of the loss
Number of subjects: 50
Study: 11887035

Group type: EXPERIMENTAL
Intervention: Antidepressant medication
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Problem-solving treatment from research nurse
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Medication and combination treatment
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Medication
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: All four treatments
Number of subjects: 155
Study: 9812111

Group type: EXPERIMENTAL
Intervention: Haloperidol 2-3 mg/day (standard dose)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Haloperidol 0.50-0.75 mg/day (low dose)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Haloperidol 2-3 mg/day (standard dose) in phase B
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Low-dose haloperidol in phase B
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo in phase B
Number of subjects: 71
Study: 7631024

Group type: EXPERIMENTAL
Intervention: 30 Gy in ten fractions, five fractions a week (5F/W)
Number of subjects: 217

Group type: COMPARATOR
Intervention: 15 Gy in three fractions, two fractions a week (2F/W)
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Both regimes (30 Gy in ten fractions and 15 Gy in three fractions)
Number of subjects: 217
Study: 2204696

Group type: EXPERIMENTAL
Intervention: Double therapy (cyclosporine and azathioprine)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Triple therapy (cyclosporine, azathioprine, and corticosteroids)
Number of subjects: 0
Study: 642793

Group type: EXPERIMENTAL
Intervention: Protected Environment (PE)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Systemic Antibiotics (SA)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Prophylactic Antibiotics (PA)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Outside Protected Environment (PE)
Number of subjects: 145

Group type: COMPARATOR
Intervention: OAP Chemotherapy
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Adriamycin-OAP + BCG
Number of subjects: 145
Study: 31760958

Group type: EXPERIMENTAL
Intervention: Salmon (750 g/week)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Cod (750 g/week)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control (normal eating habits, avoiding fish)
Number of subjects: 63
Study: 31158607

Group type: EXPERIMENTAL
Intervention: E0703 (30 mg oral administration)
Number of subjects: 0
Study: 28290765

Group type: EXPERIMENTAL
Intervention: Moderate Intensity Interval Exercise (MIIE)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: High Intensity Interval Exercise (HIIE)
Number of subjects: 11

Group type: COMPARATOR
Intervention: All exercise protocols
Number of subjects: 11
Study: 25857320

Group type: EXPERIMENTAL
Intervention: Prostate-specific antigen (PSA) screening
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prostatectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 23248223

Group type: EXPERIMENTAL
Intervention: Developmental screening using Ages and Stages Questionnaire‐II (ASQ‐II) and Modified Checklist for Autism in Toddlers (M‐CHAT) with office staff assistance
Number of subjects: 2103

Group type: EXPERIMENTAL
Intervention: Developmental screening using ASQ‐II and M‐CHAT without office staff assistance
Number of subjects: 2103

Group type: COMPARATOR
Intervention: Developmental surveillance using age‐appropriate milestones at well visits
Number of subjects: 2103
Study: 21664658

Group type: EXPERIMENTAL
Intervention: trabectedin+PLD
Number of subjects: 216
Study: 19201404

Group type: EXPERIMENTAL
Intervention: 3D power Doppler imaging
Number of subjects: 25

Group type: COMPARATOR
Intervention: 2D Doppler imaging
Number of subjects: 25
Study: 16721226

Group type: EXPERIMENTAL
Intervention: Nasojejunal (NJ) feeding
Number of subjects: 31

Group type: COMPARATOR
Intervention: Nasogastric (NG) feeding
Number of subjects: 31
Study: 15278043

Group type: EXPERIMENTAL
Intervention: Videoendoscopic elastic band ligation
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional elastic band ligation
Number of subjects: 100
Study: 11408849

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 40

Group type: COMPARATOR
Intervention: Betamethasone
Number of subjects: 40
Study: 9222732

Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg twice daily
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg three times daily
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Both groups (compliant patients)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Smokers vs Non-smokers
Number of subjects: 54

Group type: COMPARATOR
Intervention: Age comparison
Number of subjects: 54
Study: 8500696

Group type: EXPERIMENTAL
Intervention: Chronic atrophic gastritis (CAG)
Number of subjects: 742

Group type: EXPERIMENTAL
Intervention: Superficial gastritis
Number of subjects: 742

Group type: EXPERIMENTAL
Intervention: Fundic chronic atrophic gastritis
Number of subjects: 742

Group type: COMPARATOR
Intervention: Endoscopy
Number of subjects: 742

Group type: EXPERIMENTAL
Intervention: Autoimmune gastritis
Number of subjects: 742
Study: 3687313

Group type: EXPERIMENTAL
Intervention: BAY m 1099 (3 X 50 mg/day) in non-diabetic controls
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: BAY m 1099 (2 X 25 mg/day) in type II diabetics
Number of subjects: 6

Group type: COMPARATOR
Intervention: BAY o 1248 (15 mg single dose) in type II diabetics
Number of subjects: 6
Study: 29752922

Group type: EXPERIMENTAL
Intervention: Transabdominal sonography (TAS)
Number of subjects: 629

Group type: COMPARATOR
Intervention: Transvaginal sonography (TVS)
Number of subjects: 629
Study: 27871302

Group type: EXPERIMENTAL
Intervention: Glycopyrrolate
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Hyoscine hydrobromide
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 25003151

Group type: EXPERIMENTAL
Intervention: High-dose remifentanil (10 ng · mL(‐1))
Number of subjects: 126

Group type: COMPARATOR
Intervention: Low-dose remifentanil (5 ng · mL(‐1))
Number of subjects: 126
Study: 22370325

Group type: EXPERIMENTAL
Intervention: Fulvestrant (250 mg + LD regimen) plus 1 mg of anastrozole daily
Number of subjects: 514

Group type: COMPARATOR
Intervention: Anastrozole (1 mg daily) alone
Number of subjects: 514

Group type: EXPERIMENTAL
Intervention: Fulvestrant plus anastrozole
Number of subjects: 514

Group type: COMPARATOR
Intervention: Anastrozole alone
Number of subjects: 514
Study: 20088854

Group type: EXPERIMENTAL
Intervention: Checklist of Nonverbal Pain Indicators (CNPI)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Pain Assessment in Advanced Dementia (PAINAD)
Number of subjects: 60
Study: 19100067

Group type: EXPERIMENTAL
Intervention: Autoantibodies against beta(1) adrenergic receptor
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Autoantibodies against M(2) adrenergic receptor
Number of subjects: 136
Study: 15696402

Group type: COMPARATOR
Intervention: NUTRIOSE FB 30 g/d
Number of subjects: 20

Group type: COMPARATOR
Intervention: NUTRIOSE FB 45 g/d
Number of subjects: 20

Group type: COMPARATOR
Intervention: NUTRIOSE FB 60 g/d
Number of subjects: 20

Group type: COMPARATOR
Intervention: NUTRIOSE FB 80 g/d
Number of subjects: 20

Group type: COMPARATOR
Intervention: NUTRIOSE FB 10 g/d to 80 g/d
Number of subjects: 20
Study: 12133372

Group type: EXPERIMENTAL
Intervention: Phacoemulsification
Number of subjects: 68
Study: 10362215

Group type: EXPERIMENTAL
Intervention: VT resolution during the first year of life
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: VT resolution beyond the first year of life
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Presumed right VT
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Presumed left VT
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Patients free of VT and not taking antiarrhythmic drugs at last follow-up
Number of subjects: 98
Study: 7562100

Group type: EXPERIMENTAL
Intervention: 10-week moderately energy-restricted diet (80% of habitual)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (8 subjects)
Number of subjects: 24
Study: 2257739

Group type: EXPERIMENTAL
Intervention: Gyne T 380 Slimline
Number of subjects: 996

Group type: COMPARATOR
Intervention: Standard Gyne T 380
Number of subjects: 996

Group type: EXPERIMENTAL
Intervention: Both devices
Number of subjects: 996
Study: 941864

Group type: EXPERIMENTAL
Intervention: Acupuncture therapy in three different loci (unilateral loci used for weight loss, bilateral loci, unilateral loci not used for weight loss)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control period (no treatment)
Number of subjects: 24
Study: 30927126

Group type: COMPARATOR
Intervention: Control (Group A) - Forward alignment training
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Group B - Increasing sensorimotor discordance
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Group C - Decreasing sensorimotor discordance
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Group D - Varied sensorimotor discordance
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Side alignment training
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Reverse alignment training
Number of subjects: 80
Study: 29140382

Group type: EXPERIMENTAL
Intervention: Mini Dental Implants (MDIs) - 4 implants
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard-Sized Tissue-Level Implants (STL) - 2 implants
Number of subjects: 50
Study: 24550352

Group type: EXPERIMENTAL
Intervention: Regular physical exercise in senior sportsmen
Number of subjects: 3

Group type: COMPARATOR
Intervention: Sedentary seniors
Number of subjects: 3
Study: 23739274

Group type: EXPERIMENTAL
Intervention: Day AFO-wearing group (n = 56, wearing AFOs all day)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Day-night AFO-wearing group (n = 56, wearing AFOs all day and all night)
Number of subjects: 112
Study: 22165321

Group type: EXPERIMENTAL
Intervention: 0.6% triclosan irrigation
Number of subjects: 14
Study: 19803565

Group type: EXPERIMENTAL
Intervention: Acceptance
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Cognitive dissonance
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Distraction
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control
Number of subjects: 100

Group type: COMPARATOR
Intervention: Ruminative attention control
Number of subjects: 100
Study: 17063830

Group type: EXPERIMENTAL
Intervention: LI.11 group (EA at LI.11 acupoint)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: LI.10 group (EA at LI.10 acupoint)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (without acupuncture)
Number of subjects: 24
Study: 15604853

Group type: EXPERIMENTAL
Intervention: Stem-cell therapy (various approaches including direct injection, intravascular injection, and bone marrow stimulation)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Early clinical trials (various approaches)
Number of subjects: 0
Study: 11728954

Group type: EXPERIMENTAL
Intervention: Urine from preterm neonates
Number of subjects: 19

Group type: COMPARATOR
Intervention: Urine from full-term neonates
Number of subjects: 19

Group type: COMPARATOR
Intervention: Urine from healthy adults
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Age progression in preterm neonates
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Correlation between [tm] and urinary citrate level
Number of subjects: 19
Study: 9229602

Group type: EXPERIMENTAL
Intervention: Antazolin/Tetryzolin eye drops
Number of subjects: 69

Group type: COMPARATOR
Intervention: Levocabastine eye drops
Number of subjects: 69
Study: 7893587

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate, 200 micrograms twice daily for 2 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: No therapy (Control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate
Number of subjects: 0
Study: 3315279

Group type: EXPERIMENTAL
Intervention: Platinum drugs (specific drugs not mentioned)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 29077192

Group type: EXPERIMENTAL
Intervention: Unilateral inferior oblique graded recession-anteriorization (Group UNI)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Bilateral inferior oblique graded recession-anteriorization (Group BI)
Number of subjects: 34
Study: 27232535

Group type: EXPERIMENTAL
Intervention: Ferrous gluconate daily (37.5 mg iron)
Number of subjects: 215

Group type: COMPARATOR
Intervention: No iron supplementation
Number of subjects: 215
Study: 26212249

Group type: EXPERIMENTAL
Intervention: Dynamic ergometer
Number of subjects: 11

Group type: COMPARATOR
Intervention: Stationary ergometer
Number of subjects: 11
Study: 23902888

Group type: EXPERIMENTAL
Intervention: Lupus enteritis group (n = 66)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Non-lupus related abdominal pain group (n = 73)
Number of subjects: 139
Study: 21916688

Group type: EXPERIMENTAL
Intervention: Standard expressive writing intervention
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Enhanced expressive writing intervention
Number of subjects: 258

Group type: COMPARATOR
Intervention: Control condition (nonemotional topic writing)
Number of subjects: 258
Study: 19034253

Group type: EXPERIMENTAL
Intervention: H7-insomnia control (acupressure device on HT 7 points)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: H7-insomnia control
Number of subjects: 40
Study: 16637039

Group type: EXPERIMENTAL
Intervention: Sertraline (50 mg)
Number of subjects: 31